Folgen
Franz X. Vollenweider
Titel
Zitiert von
Zitiert von
Jahr
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
FX Vollenweider, MFI Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, ...
Neuroreport 9 (17), 3897-3902, 1998
8371998
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia
D Umbricht, L Schmid, R Koller, FX Vollenweider, D Hell, DC Javitt
Archives of general psychiatry 57 (12), 1139-1147, 2000
6542000
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
FX Vollenweider, M Kometer
Nature Reviews Neuroscience 11 (9), 642, 2010
6442010
Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers
FX Vollenweider, A Gamma, M Liechti, T Huber
Neuropsychopharmacology 19 (4), 241-251, 1998
5731998
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
FX Vollenweider, KL Leenders, C Scharfetter, P Maguire, O Stadelmann, ...
Neuropsychopharmacology 16 (5), 357-372, 1997
4551997
Serotonin research: contributions to understanding psychoses
MA Geyer, FX Vollenweider
Trends in pharmacological sciences 29 (9), 445-453, 2008
4522008
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG)
FX Vollenweider, KL Leenders, C Scharfetter, A Antonini, P Maguire, ...
European neuropsychopharmacology 7 (1), 9-24, 1997
4161997
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
E Studerus, M Kometer, F Hasler, FX Vollenweider
Journal of psychopharmacology 25 (11), 1434-1452, 2011
4112011
Gender differences in the subjective effects of MDMA
ME Liechti, A Gamma, FX Vollenweider
Psychopharmacology 154 (2), 161-168, 2001
4102001
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission …
FX Vollenweider, KL Leenders, I Øye, D Hell, J Angst
European Neuropsychopharmacology 7 (1), 25-38, 1997
4071997
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
E Studerus, A Gamma, FX Vollenweider
PloS one 5 (8), e12412, 2010
4062010
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study
F Hasler, U Grimberg, MA Benz, T Huber, FX Vollenweider
Psychopharmacology 172 (2), 145-156, 2004
3892004
A systems model of altered consciousness: integrating natural and drug-induced psychoses
FX Vollenweider, MA Geyer
Brain research bulletin 56 (5), 495-507, 2001
3632001
Acute effects of lysergic acid diethylamide in healthy subjects
Y Schmid, F Enzler, P Gasser, E Grouzmann, KH Preller, FX Vollenweider, ...
Biological psychiatry 78 (8), 544-553, 2015
3292015
Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram
ME Liechti, C Baumann, A Gamma, FX Vollenweider
Neuropsychopharmacology 22 (5), 513-521, 2000
3222000
5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C] raclopride
FX Vollenweider, P Vontobel, D Hell, KL Leenders
Neuropsychopharmacology 20 (5), 424-433, 1999
2891999
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia
K Ludewig, MA Geyer, FX Vollenweider
Biological psychiatry 54 (2), 121-128, 2003
2802003
Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans
FX Vollenweider, P Vontobel, I Øye, D Hell, KL Leenders
Journal of psychiatric research 34 (1), 35-43, 2000
2762000
Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans
ME Liechti, MR Saur, A Gamma, D Hell, FX Vollenweider
Neuropsychopharmacology 23 (4), 396-404, 2000
2752000
Prediction of psilocybin response in healthy volunteers
E Studerus, A Gamma, M Kometer, FX Vollenweider
PloS one 7 (2), e30800, 2012
2712012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20